CoChat

Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men

Leder, Benjamin Z., Finkelstein, Joel S. · 2005 · Osteoporosis International

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Abstract

Both estrogens and androgens play important roles in skeletal development and maintenance in men. The relative importance of estrogens and androgens in male bone metabolism, however, remains undefined. Anastrozole is an oral aromatase inhibitor that decreases estrogen production and increases androgen production in men. Currently, anastrozole is being investigated as a potential agent for the treatment of hypogonadism in aging men. Because anastrozole lowers estrogen levels and raises androgen levels, its effect on bone metabolism is difficult to predict. To assess the effects of anastrozole on bone turnover, we randomized 37 elderly (ages 62-74) mildly hypogonadal men (serum testosterone <350 ng/dl) to receive either anastrozole 1 mg daily (n=12), anastrozole 1 mg twice weekly (n=11), or daily placebo (n=14) for 12 weeks. Serum gonadal steroid levels, serum and urine biochemical markers of bone turnover, serum osteoprotegerin, and total body bone mineral density were measured at baseline and week 12. Mean serum levels of total and bioavailable testosterone increased substantially in both treated groups. Specifically, mean +/- SD bioavailable testosterone levels increased from 99+/-31 ng/dl to 207+/-65 ng/dl in the group receiving 1 mg of anastrozole daily and from 115+/-37 ng/dl to 178+/-55 ng/dl in the subjects receiving 1 mg of anastrozole twice weekly ( p <0.001 vs placebo for both groups). Serum estradiol levels decreased modestly in both treated groups (from 26+/-8 pg/m…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00198-005-1890-8

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 78 references

Cited by

See all 44

Metadata

Authors
Leder, B. Z., & Finkelstein, J. S.
Affiliations
Massachusetts General Hospital (US)
Corresponding author
Leder, Benjamin Z.
Venue
Osteoporosis International
Published
2005-04-23
Volume
16
Issue
12
Pages
1487-1494
ISSN
  • 0937-941X (ISSN-L)
  • 1433-2965
OpenAlex
W2017930983
Cited by
44
References
78
Citations by year
2024: 1 · 2022: 4 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 1 · 2016: 11 · 2015: 1 · 2014: 3 · 2012: 2
FWCI
2.22
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Osteoporosis International (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (K24DK002759)
  • National Center for Research Resources (M01RR001066, K23RR016310, RR-1066)
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
anastrozole, aromatase inhibitors, male hypogonadism, older men, bone metabolism, testosterone, estradiol, bone turnover markers, bone mineral density, osteoprotegerin, N-telopeptide, deoxypyridinoline, osteocalcin, androgen production, bone resorption, bone formation, hormone replacement therapy
MeSH terms
Anastrozole, Aged, Bone and Bones, Bone Resorption, Estradiol, Glycoproteins, Humans, Hypogonadism, Male, Nitriles, Testosterone, Triazoles, Biomarkers, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Aromatase Inhibitors, Osteoprotegerin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. https://app.cochat.ai/papers/10.1007/s00198-005-1890-8
The paper
Leder, B. Z., & Finkelstein, J. S. (2005). Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporosis International. https://doi.org/10.1007/s00198-005-1890-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.